Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effectively immediately.
Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.
Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
Basilea Pharmaceutica’s Basilea Pharmaceutica International Ltd. has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea’s antibiotic Zevtera/Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and Israel.
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.